OncoSil Medical Ltd (ASX:OSL) continues to make steady progress, having recruited 23 subjects into the study group of its Global Pancreatic Cancer Clinical Study Programme.
The company’s lead product, OncoSil™, is a targeted radioactive isotope, implanted directly into a patient’s pancreatic tumours via an endoscopic ultrasound.
Treatment with OncoSil is intended to deliver more concentrated and localised beta radiation compared to external beam radiation.
Importantly, 10 subjects in the study group have now been successfully implanted with the OncoSil device across four study sites.
Positive interim data relating to tumour response and disease control has been received from subjects implanted during the current phase of the programme.
Study investigators have been encouraged by the clinical data that have emerged so far from the study.
Oncosil intends to share a study progress update at the European Association of Nuclear Medicine in Vienna on 21 October.
The company will continue to recruit subjects beyond the initial 20 subject target to gather additional valuable clinical experience.
Recruitment efforts for the global study continue to accelerate across all 10 activated centres in Australia, the UK and the U.S.
Significantly, the data gathered to date will contribute to the 20-subject Supplemental Data Request to secure CE Marking, Oncosil’s immediate focus.